![]() |
市場調查報告書
商品編碼
2069207
基於遊戲化的注意力訓練市場預測至2034年:全球分析(按組成部分、目標疾病、遊戲機制、年齡層、最終用戶和地區分類)Gamified Attention Training Market Forecasts to 2034 - Global Analysis By Component (Software Platforms, Hardware and Services), Target Condition, Game Mechanic, Age Group, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球基於遊戲化的注意力訓練市場預計將在 2026 年達到 23 億美元,並在預測期內以 18.6% 的複合年成長率成長,到 2034 年達到 90 億美元。
基於遊戲化的注意力訓練是一種認知發展方法,它利用遊戲化活動、互動任務、獎勵機制和績效回饋來提升個體的專注力、持續注意力和注意力控制能力。此方法融合了行為心理學、神經科學和遊戲設計的原理,創造了一個引人入勝的環境,鼓勵個體反覆練習與注意力相關的任務。這種方法透過結構化的目標設定、進展追蹤和基於成就的獎勵來激發使用者的積極性,從而提高選擇性注意力、持續注意力和認知加工效率。
過動症診斷率上升
兒童和成人注意力不足/過動症 (ADHD) 的臨床認知度和診斷率不斷提高,正顯著推動對數位治療方法的需求成長。北美和歐洲的醫療保健系統優先考慮非藥物療法,以補充或減少藥物依賴。家長和看護者正在積極尋找具有吸引力、循證且適合家庭使用的解決方案。 FDA 批准的數位療法的保險報銷範圍不斷擴大,降低了獲取這些療法的門檻。臨床需求與數位科技普及的融合,正在加速全球醫療保健、教育和消費者健康領域的數位療法應用。
有限的臨床證據
許多基於遊戲化的認知訓練產品缺乏大規模、長期的隨機對照試驗證據,這削弱了醫生的信心,並影響了保險公司的報銷決策。美國食品藥物管理局(FDA)和類似的監管機構要求在宣稱療效之前進行嚴格的臨床驗證。關於訓練的認知技能在多大程度上能轉化為現實生活中的功能性結果,學術界仍在爭論不休。進行臨床檢驗研究的成本對於中小企業來說太昂貴。證據的缺乏阻礙了這些產品融入醫療保健系統,並限制了其在消費者健康領域之外的市場滲透。
與遠端醫療平台整合
將遊戲化注意力訓練模組整合到現有的遠距遠端醫療和電子健康記錄平台中,能夠顯著提升應用普及率和收入成長。醫療服務提供者正在尋求成熟的數位輔助工具,以便在現有的診療流程中進行遠距處方和監測。與領先的遠距遠端醫療提供者合作,無需直接增加獲客成本即可擴大服務覆蓋範圍。遠端患者監護的報銷代碼開闢了新的計費管道。後疫情時代虛擬醫療的加速普及,有助於維持臨床醫師和病患對可處方數位化治療方案的接受度。
競爭的健康應用程式
大量缺乏臨床證據、聲稱能提升注意力的通用型腦力訓練和健康應用程式的湧現,導致消費者困惑和市場碎片化。低價或免費的消費者應用程式削弱了經臨床檢驗的高級產品的價格競爭力。擁有龐大用戶群、行銷資源和分銷管道的大型科技平台的進入,加劇了專業公司面臨的競爭。監管機構對健康聲稱和治療聲稱之間的區別,也使消費者教育變得更加複雜。與傳統藥物處方相比,醫生對數位療法的不熟悉阻礙了其在臨床實踐中的應用。
新冠疫情加速了數位醫療的普及,並導致居家認知支援工具的需求激增,因為學校停課和遠距辦公擾亂了人們的注意力和專注力。疫情初期供應鏈和研發方面的中斷被遠端醫療的快速發展所抵銷。疫情後,遠距學習和混合辦公模式的建立確立了對注意力訓練解決方案的長期需求。與疫情相關的注意力和專注力障礙診斷病例的增加擴大了目標臨床患者群體。
在預測期內,軟體平台細分市場預計將佔據最大佔有率。
在預測期內,軟體平台領域預計將佔據最大的市場佔有率,這主要得益於雲端發送類型和行動應用程式作為遊戲化認知訓練主要手段的主導地位。軟體平台無需依賴硬體即可在臨床、教育和消費管道進行可擴展部署。基於訂閱的收入模式為投資者和營運商創造了極具吸引力的持續收入來源。持續的功能更新和自適應演算法改進無需更換實體產品即可實現。該領域受益於低分銷成本、全球覆蓋範圍以及與遠端醫療和電子健康記錄基礎設施的整合能力。
在預測期內,神經回饋整合遊戲領域預計將實現最高的複合年成長率。
在預測期內,神經回饋整合遊戲領域預計將呈現最高的成長率,這主要得益於消費級腦電圖(EEG)硬體的小型化和遊戲化訓練軟體的融合。即時神經訊號處理技術能夠實現生物回饋療法迴路,進而在遊戲過程中直接增強注意力狀態,進一步提升其治療效果。臨床上對客觀、可衡量的認知訓練結果日益成長的興趣正在推動神經回饋技術的應用。硬體成本的降低和無線連接能力的提升提高了消費者的使用便利性。神經回饋數位療法獲得監管部門的批准,為其商業性合法性提供了保障,並開啟了與保險公司就報銷事宜進行磋商的進程。
在預測期內,北美預計將佔據最大的市場佔有率,這主要得益於其較高的注意力不足過動症(ADHD)診斷率、先進的數位健康基礎設施以及有利於數位療法的監管環境。美國在該領域處於領先地位,擁有經FDA批准的處方箋位療法產品和完善的遠端醫療報銷體系。總部位於北美的領先科技和醫療保健公司正積極投資認知健康平台。消費者對優質數位健康和治療產品的支付意願也推動了產生收入。聯邦政府對心理健康技術研究的資助也全部區域的創新發展提供了持續的動力。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於數位健康基礎設施的快速擴張、人們對注意力不足過動症(ADHD)的認知度不斷提高,以及中國、日本、韓國和印度等國政府對心理健康計畫的投入。智慧型手機普及率的不斷提高,使得以行動優先、遊戲化的方式進行大規模培訓成為可能。重視教育的文化推動了兒童和青少年對認知增強工具的需求。本土科技公司正以具競爭力的價格進軍認知健康軟體領域。不斷完善的區域法規結構,為數位治療產品的核准提供了便利,也進一步刺激了投資。
According to Stratistics MRC, the Global Gamified Attention Training Market is accounted for $2.3 billion in 2026 and is expected to reach $9.0 billion by 2034 growing at a CAGR of 18.6% during the forecast period. Gamified Attention Training is a cognitive development approach that uses game-based activities, interactive challenges, reward systems, and performance feedback to enhance an individual's ability to focus, sustain concentration, and manage attentional control. It integrates principles of behavioral psychology, neuroscience, and game design to create engaging environments that encourage repeated practice of attention-related tasks. The method is designed to improve selective attention, sustained attention, and cognitive processing efficiency by motivating users through structured objectives, progress tracking, and achievement-based incentives.
Rising ADHD diagnosis rates
Increasing clinical recognition and diagnostic rates of attention deficit hyperactivity disorder among children and adults are creating substantial demand for digital therapeutic alternatives. Healthcare systems in North America and Europe are prioritizing non-pharmacological interventions to complement or reduce medication dependence. Parents and caregivers actively seek engaging, evidence-based home-use solutions. Insurance reimbursement pathways for FDA-authorized digital therapeutics are expanding, lowering access barriers. The convergence of clinical need and digital accessibility accelerates adoption across healthcare, education, and consumer wellness channels globally.
Limited clinical evidence base
The absence of large-scale, long-term randomized controlled trial evidence for many gamified cognitive training products undermines physician confidence and payer reimbursement decisions. Regulatory scrutiny from the FDA and equivalent bodies requires rigorous clinical substantiation before therapeutic claims can be made. Academic debate around the transfer of trained cognitive skills to real-world functional outcomes persists. Development costs for clinical validation studies are prohibitive for smaller companies. These evidence gaps slow healthcare system integration and restrict market penetration beyond consumer wellness segments.
Telehealth platform integration
Integration of gamified attention training modules into established telehealth and electronic health record platforms creates significant distribution and revenue expansion opportunities. Healthcare providers seek validated digital adjunct tools that can be prescribed and monitored remotely within existing care workflows. Partnerships with major telehealth operators amplify reach without direct consumer acquisition costs. Remote patient monitoring reimbursement codes enable new billing pathways. The acceleration of virtual care adoption following the pandemic sustains clinician and patient receptivity to prescription digital therapeutic solutions.
Competing wellness applications
The proliferation of general brain training and wellness applications offering attention improvement features without clinical substantiation creates consumer confusion and market fragmentation. Low-cost or free consumer apps undercut pricing for premium, clinically validated products. Large technology platform entrants with established user bases, marketing resources, and distribution channels pose competitive threats to specialized companies. Regulatory differentiation between wellness and therapeutic claims complicates consumer education. Physician unfamiliarity with digital therapeutics categories slows clinical adoption relative to conventional medication prescribing.
The COVID-19 pandemic accelerated digital health adoption and created acute demand for home-based cognitive support tools as school closures and remote work disrupted attention and focus routines. Initial supply chain and development disruptions were offset by rapid telehealth expansion. Post-pandemic, sustained remote learning and hybrid work environments established long-term demand for attention training solutions. Increased diagnosis of pandemic-related attention and focus disorders broadened the addressable clinical population.
The software platforms segment is expected to be the largest during the forecast period
The software platforms segment is expected to account for the largest market share during the forecast period, due to the dominant role of cloud-delivered and mobile applications as the primary delivery mechanism for gamified cognitive training. Software platforms enable scalable deployment across clinical, educational, and consumer channels without hardware dependencies. Subscription-based revenue models generate recurring income streams attractive to investors and operators. Continuous feature updates and adaptive algorithm improvements are achievable without physical product replacement. The segment benefits from low distribution costs, global reach, and integration capabilities with telehealth and electronic health record infrastructure.
The neurofeedback-integrated games segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the neurofeedback-integrated games segment is predicted to witness the highest growth rate, driven by the convergence of consumer EEG hardware miniaturization with gamified training software. Real-time neural signal processing enables biofeedback loops that directly reinforce attentional states during gameplay, elevating therapeutic efficacy claims. Clinical interest in objective, measurable cognitive training outcomes supports neurofeedback adoption. Declining hardware costs and improved wireless connectivity expand consumer accessibility. Regulatory clearances for neurofeedback-enabled digital therapeutics provide commercial legitimacy and open reimbursement discussions with payers.
During the forecast period, the North America region is expected to hold the largest market share, due to the high prevalence of diagnosed ADHD, advanced digital health infrastructure, and favorable regulatory pathways for digital therapeutics. The United States leads with FDA-cleared prescription digital therapeutic products and established telehealth reimbursement frameworks. Major technology and healthcare companies headquartered in North America actively invest in cognitive health platforms. Consumer willingness to pay for premium digital wellness and therapeutic products supports revenue generation. Federal funding for mental health technology research sustains innovation pipelines across the region.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding digital health infrastructure, increasing ADHD awareness, and government investment in mental health programs across China, Japan, South Korea, and India. Growing smartphone penetration enables mobile-first gamified training delivery at a population scale. Education-focused cultures drive demand for cognitive enhancement tools among children and adolescents. Local technology companies are entering the cognitive health software segment with competitive pricing. Regional regulatory frameworks are evolving to accommodate digital therapeutic product approvals, further stimulating investment.
Key players in the market
Some of the key players in Gamified Attention Training Market include Akili Interactive Labs, Inc., Pear Therapeutics, Inc., CogniFit Inc., Lumos Labs, Inc. [Lumosity], Peak [Brainbow Ltd.], Posit Science Corporation, MindMaze SA, NeuroPlus Inc., Atentiv Inc., EndeavorRx [Akili], Nintendo Co., Ltd., Sony Group Corporation, Microsoft Corporation, Apple Inc., Total Brain Limited and Sanvello Health, Inc..
In May 2026, Akili Interactive Labs, Inc. launched an updated EndeavorRx platform incorporating real-time neurofeedback integration and expanded clinical monitoring dashboards for pediatric ADHD telehealth providers across twelve U.S. health systems.
In April 2026, Posit Science Corporation partnered with a major U.S. Medicare Advantage insurer to offer clinically validated gamified cognitive training programs as covered preventive benefits for enrolled beneficiaries aged sixty-five and above.
In March 2026, CogniFit Inc. introduced a multilingual gamified attention assessment and training suite targeting school districts in Spain and Latin America, receiving endorsement from three regional educational psychology associations.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.